FDA Approves Praluent (alirocumab) to Prevent Heart Attack, Stroke and Unstable Angina Requiring Hospitalization

PARIS and TARRYTOWN, NY– April 26, 2019– The U.S. Food and Drug Administration (FDA) has approved Praluent (alirocumab) to reduce the risk of heart attack, stroke, and unstable angina requiring hospitalization in adults with...
Source: Drugs.com - New Drug Approvals - Category: Drugs & Pharmacology Source Type: news

Related Links:

Conclusion: GFR-specific risk-based cutoffs for PTH1 –84 and FGF-23 may facilitate more meaningful risk stratification in advanced CKD than current GFR-agnostic reference ranges derived from healthy adults. This may be most applicable in those with severely reduced GFR.Am J Nephrol
Source: American Journal of Nephrology - Category: Neurology Source Type: research
AbstractPurpose of the ReviewRecently, several large randomized studies and recommendations regarding patient blood management (PBM) in cardiac surgery were published. This review summarizes the current evidence relating to modern strategies in PBM from the perspective of the cardiovascular anesthesiologist.Recent FindingsPreoperative anemia should be early detected and adequately managed. In patients with intake of anticoagulants or platelet inhibitors, timely and specific stopping should be respected. Specific modification of cardiopulmonary bypass (CPB) systems aiming to reduce hemodilution and conserve patients ’...
Source: Current Anesthesiology Reports - Category: Anesthesiology Source Type: research
Malondialdehyde (MDA) is by-product of lipid peroxidation as in oxidized low-density lipoprotein. We here studied the association between IgG antibodies against Malondialdehyde (anti-MDA) and risk of cardiovascular events such as stroke, angina and myocardial infraction in this cohort. Low levels of IgG anti-MDA conjugated with human serum albumin concentrations were measured by Enzyme Linked Immunosorbent Assay (ELISA). The association between IgG anti-MDA. 84 month's follow-ups were conducted in Stockholm County for 60-year-old men and women in which the risk factors associated in the screening of cardiovascular events f...
Source: Heart, Lung and Circulation - Category: Cardiology Authors: Tags: 111 Source Type: research
Background: In type 2 diabetes, the temporal proximity of an atherosclerotic cardiovascular (CV) event can impact prognosis, but whether timing influences sodium glucose co-transporter 2 inhibitor effects is unknown. We explored the association of time from last qualifying CV event before randomization (myocardial infarction [MI], stroke, coronary artery disease or peripheral arterial disease) with CV outcomes and benefit of empagliflozin (EMPA) in EMPA-REG OUTCOME.
Source: Heart, Lung and Circulation - Category: Cardiology Authors: Tags: 416 Source Type: research
This study sought to investigate what could be learned from how these men have fared. The men were born in 1925-1928 and similar health-related data from questionnaires, physical examination, and blood samples are available for all surveys. Survival curves over various variable strata were applied to evaluate the impact of individual risk factors and combinations of risk factors on all-cause deaths. At the end of 2018, 118 (16.0%) of the men had reached 90 years of age. Smoking in 1974 was the strongest single risk factor associated with survival, with observed percentages of men reaching 90 years being 26.3, 25.7, ...
Source: Fight Aging! - Category: Research Authors: Tags: Newsletters Source Type: blogs
Publication date: Available online 21 June 2019Source: Canadian Journal of CardiologyAuthor(s): Mark Canney, Mila Tang, Lee Er, Sean J. Barbour, Ognjenka Djurdjev, Adeera Levin, CanPREDDICT InvestigatorsAbstractBackgroundUsing standard cut-offs derived from healthy adults, high-sensitivity cardiac troponin T (hs-cTnT) and N-terminal pro-B-type natriuretic peptide (NT-proBNP) are frequently elevated in patients with reduced glomerular filtration rate (GFR), with unclear implications. We sought to compare GFR-specific cut-offs of each biomarker to standard cut-offs for discrimination of cardiovascular risk in asymptomatic pa...
Source: Canadian Journal of Cardiology - Category: Cardiology Source Type: research
Publication date: Available online 21 June 2019Source: American Heart JournalAuthor(s): Bernardete Weber, Ângela C Bersch-Ferreira, Camila R Torreglosa, Aline Marcadenti, Enilda S Lara, Jacqueline T da Silva, Rosana P Costa, Renato H N Santos, Otavio Berwanger, Rosa Bosquetti, Raira Pagano, Luis G S Mota, Juliana D de Oliveira, Rafael M Soares, Andrea P Galante, Suzana A da Silva, Fernando G Zampieri, Cristiane Kovacs, Fernanda C Amparo, Priscila MoreiraAbstractBackgroundAppropriate dietary recommendations represent a key part of secondary prevention in cardiovascular disease (CVD).ObjectiveWe evaluated the effective...
Source: American Heart Journal - Category: Cardiology Source Type: research
Conclusions: Genotype-guided strategies could reduce the rates of cardiovascular events without increasing bleeding events compared with conventional treatment in ACS. Future multi-center genotype-based RCTs are required to confirm these findings. PMID: 31215825 [PubMed - as supplied by publisher]
Source: Biomarkers - Category: Research Tags: Biomarkers Source Type: research
Conclusion: Introducing extended-duration VTE prophylaxis with betrixaban in the UK would accrue substantial savings annually over the next 5 years compared to current prophylaxis. Clinical trial registration: www.clinicaltrials.gov identifier is NCT01583218. PMID: 31215264 [PubMed - as supplied by publisher]
Source: Expert Review of Pharmacoeconomics and Outcomes Research - Category: Health Management Tags: Expert Rev Pharmacoecon Outcomes Res Source Type: research
Patients whose surgeons had been reported for unprofessional behavior were at increased risk for complications such as wound infections, pneumonia, blood clots, kidney failure, stroke and heart attack.
Source: WebMD Health - Category: Consumer Health News Source Type: news
More News: Cardiology | Drugs & Pharmacology | Food and Drug Administration (FDA) | Heart | Heart Attack | Stroke